

Note: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.

(Securities Code 4694)

June 8, 2023

(Start of measures for electronic provision: June 7, 2023)

To Shareholders with Voting Rights:

Kensuke Kondo
President and Representative Director
BML, Inc.
5-21-3 Sendagaya, Shibuya-ku, Tokyo

NOTICE OF THE 68TH ANNUAL GENERAL MEETING OF SHAREHOLDERS

We would like to express our appreciation for your continued support and patronage.

We are pleased to inform you that the 68th Annual General Meeting of Shareholders of BML, Inc. (the “Company”) will be held for the purposes as described below.

In convening this Annual General Meeting of Shareholders, the Company has taken measures to provide information electronically, and posted matters subject to the electronic provision measures on the following website.

The Company’s website:

<http://www.bml.co.jp/eng/ir/index.html>

In addition to the website above, we post them on the following website.

Tokyo Stock Exchange’s website:

<https://www2.jpx.co.jp/tseHpFront/JJK020010Action.do>

Please access the Tokyo Stock Exchange (TSE) website above and enter our company name or securities code (4694). Then, click "Basic Information" and “Documents for Public Inspection/PR Information” to search “Notice of General Shareholders Meeting/Informational Materials for a General Shareholders Meeting” under “Filed information available for public inspection. ”

Depending on the spread of COVID-19 infection as of the date of the meeting and your health condition, we ask you to carefully consider your attendance at the annual general meeting of shareholders as well as the exercise of your voting rights in writing or via the Internet.

Please review the Reference Documents for the General Meeting of Shareholders included in the matters subject to the electronic provision measures, and exercise your voting rights by no later than 5:30 p.m. on Wednesday, June 28, 2023, Japan time.

- 1. Date and Time:** Thursday, June 29, 2023 at 10:00 a.m., Japan time
2. Place: Nishiki, South Tower 4F, Keio Plaza Hotel
2-2-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo, Japan
The number of seats available at the venue will be limited as we leave enough space between seats. Therefore, you may be denied admission even if you visit the venue. Thank you very much for your understanding in advance.

3. Meeting Agenda:

- Matters to be reported:**
1. Business Report, Consolidated Financial Statements for the Company's 68th Fiscal Year (April 1, 2022–March 31, 2023) and results of audits of the Consolidated Financial Statements by the Accounting Auditor and the Board of Corporate Auditors
 2. Non-consolidated Financial Statements for the Company's 68th Fiscal Year (April 1, 2022–March 31, 2023)

Proposals to be resolved:

- Proposal 1:** Distribution of Surplus
Proposal 2: Partial Amendments to the Articles of Incorporation
Proposal 3: Election of 9 Directors
Proposal 4: Election of 1 Substitute Corporate Auditor

- When attending the meeting, please submit the enclosed Voting Rights Exercise Form at the reception desk.
- You can exercise your voting rights by mail or electronic media (via the Internet, etc.). By following “Guidance for Exercise of Voting Rights” on pages 5 and 6 of the Japanese version of this document, please exercise your voting rights by no later than 5:30 p.m. on Wednesday, June 28, 2023, Japan time.
- In the event that voting rights are exercised multiple times via the Internet, etc., only the final vote submitted shall be considered valid.
- In the event that voting rights are exercised in duplicate by mailing the Voting Rights Exercise Form and via the Internet, etc., the voting rights exercised through the Internet, etc. shall be considered valid.
- If revisions are made to the matters subject to the electronic provision measures, the details of the revisions will be posted on the aforementioned websites.
- Of the matters subject to the electronic provision measures, the following materials are not included in the notice of this annual general meeting of shareholders in accordance with relevant laws and regulations and the provisions of Article 16, Paragraph 2 of the Company's Articles of Incorporation. Accordingly, the documents are parts of the documents the Corporate Auditors and Accounting Auditor audited when they prepared their respective audit reports.
 - “System for ensuring the properness of the operations”
 - “Overview of the system for ensuring the properness of the operations”
 - “Consolidated statements of changes in shareholder's equity”
 - “Notes to consolidated financial statements”
 - “Non-consolidated statement of changes in equity”
 - “Notes to non-consolidated financial statements”

<Notes to shareholders>

- We may update the above measures depending upon the situation of the spread of the disease and announcements made by the government until the day of the General Meeting of Shareholders. Please check the Company's website (<http://www.bml.co.jp>) on the Internet for the transmission of information.
- If you exercise your voting rights in advance, we would ask you to do so via the Internet to the extent possible.
- Due to a change in the government's basic policy for dealing with COVID-19 infection, wearing face masks is left to the judgment of individuals. In attending the General Meeting of Shareholders, you are kindly asked to decide whether or not to wear a mask, considering your physical condition and the risk of infection.
- In case that you are not feeling well, please refrain from attending the meeting.
- Operation staff of the General Meeting of Shareholders will take their temperatures, check their physical conditions, and wear face masks.

Reference Documents for the General Meeting of Shareholders

Proposals and References

Proposal 1: Distribution of Surplus

The Company recognizes the appropriate return of profits to shareholders as one of its important management priorities and intends to strive for improvement of the dividend level commensurate with the consolidated financial results based on the basic policy of maintaining continuous, stable dividends.

The year-end dividend of surplus for this year shall be paid as follows, based on such basic policy.

Items Related to the Year-end Dividend

(1) Type of dividend property
Cash

(2) Items related to the allocation of dividend property and the total amount
60.0 yen per common share of the Company
Total amount: 2,341,161,720 yen

The annual dividend for this year will be 100.0 yen per share including the interim dividend of 40.0 yen per share which has been already paid.

(3) Date the distribution of surplus comes into effect
June 30, 2023

Proposal 2: Partial Amendments to the Articles of Incorporation

1. Reasons for the amendments

The Company shall amend Article 2 (Purpose) of the current Articles of Incorporation to include the operation of childcare facilities. The amendment aims to support the Company's employees who raise children and the workers at companies nearby as a part of our social action program by accepting their children and children in the local community.

2. Details of the amendments

The details of the amendments are as follows.

(Proposed amendments are underlined.)

Current	Proposed Amendments
<p>Article 2 (Purpose)</p> <p>The purposes of the Company shall be to engage in the following businesses:</p> <p>1. to 29. (Omitted)</p> <p>(Newly established)</p> <p><u>30.</u> research and development related to each of the foregoing items and any other incidental businesses.</p>	<p>Article 2 (Purpose)</p> <p>The purposes of the Company shall be to engage in the following businesses:</p> <p>1. to 29. (Unchanged)</p> <p><u>30. Operation of childcare facilities</u></p> <p><u>31.</u> research and development related to each of the foregoing items and any other incidental businesses.</p>


Proposal 3: Election of 9 Directors

The terms of office of all 9 Directors will expire at the conclusion of this General Meeting of Shareholders. Accordingly, the Company proposes to elect 9 Directors.

The candidates for Directors are as follows. Matters on the candidates for Directors are provided on pages 10 to 14.


No.	Name	Positions and responsibilities in the Company	Attendance at meetings of the Board of Directors
1	Kensuke Kondo (Reappointment)	President and Representative Director	100.0% 17 out of 17 times
2	Nobuki Arai (Reappointment)	Representative Director; Vice President in charge of BML Clinical Testing Headquarters and in charge of Management Division; Director, BML General Laboratory; General Manager, Overseas Business Office	100.0% 17 out of 17 times
3	Norihisa Takebe (Reappointment)	Director; Senior Executive Officer; General Manager, Planning Division; General Manager, Corporate Planning Department; General Manager, Sales Management Department; General Manager, Accounting Department; General Manager, Related Business Department	100.0% 17 out of 17 times
4	Hideaki Osawa (Reappointment)	Director; Operating Officer; General Manager, Sales Management Division; General Manager, Sales Promotion Headquarters; General Manager, Solution Proposal Department; General Manager, Medical Research Business Division	100.0% 17 out of 17 times
5	Kenji Shibata (Reappointment)	Director; Operating Officer; General Manager, BML Clinical Testing Headquarters; General Manager, Inspection Planning Department, General Manager, General Laboratory Second Clinical Testing Department; General Manager, General Laboratory Fourth Clinical Testing Department	100.0% 13 out of 13 times

No.	Name	Positions and responsibilities in the Company	Attendance at meetings of the Board of Directors
6	Yuji Yamashita (Reappointment)	Director; Operating Officer; General Manager, System Division	100.0% 13 out of 13 times
7	Yukiko Yoritaka (Reappointment) (Outside) (Independent)	Director	100.0% 17 out of 17 times
8	Tatsuharu Arai (Reappointment) (Outside) (Independent)	Director	100.0% 17 out of 17 times
9	Shigeru Osawa (Reappointment) (Outside) (Independent)	Director	100.0% 13 out of 13 times


No.	Name (Date of birth)	Past experience, positions and responsibilities in the Company	Number of shares of the Company held
1	 <p data-bbox="188 667 400 786">Kensuke Kondo (September 18, 1966) (Reappointment)</p>	<p data-bbox="432 271 1209 459"> May 1994 Obtained a medical license June 1994 Director of the Company June 2004 Operating Officer in charge of medical science June 2006 Director; Operating Officer in charge of medical science January 2014 President and Representative Director To present </p> <p data-bbox="432 465 1289 750"> [Significant concurrent positions] • Chairman and Representative Director, Daiichi Kishimoto Clinical Laboratories, Inc. • Chairman and Representative Director, Okayama Medical Laboratory Company • Chairman and Representative Director, Kyodo Igaku Laboratories, Inc. • Chairman and Representative Director, PCL Japan, Inc. • Chairman and Representative Director, Japan Clinical Service, Inc. • Chairman and Representative Director, OPL, Inc. • President and Representative Director, BML Planning, Inc. • President and Representative Director, Estate Kogyo Limited Company </p> <p data-bbox="432 779 1289 1019"> (Reasons for nomination) Dr. Kensuke Kondo has abundant experience and deep insight on overall medical industry from his experience as a doctor. Since assuming position as Representative Director in January 2014, he has been leading the Group's management. Based on his wealth of achievement from his excellent leadership, the Company has judged that he is personnel necessary to increase future corporate value of the Group, and therefore nominates him again as a candidate for Director. </p>	3,169,988


No.	Name (Date of birth)	Past experience, positions and responsibilities in the Company	Number of shares of the Company held
2	 <p data-bbox="197 680 391 801">Nobuki Arai (March 30, 1960) (Reappointment)</p>	<p data-bbox="427 271 1283 808"> May 1989 Obtained a medical license June 2005 Outside Corporate Auditor of the Company June 2009 Director of the Company December 2009 Director; Executive Officer; Director, BML General Laboratory June 2015 Director; Senior Executive Officer in charge of Sales Management Division; Director, BML General Laboratory June 2017 Representative Director; Senior Executive Officer; General Manager, Planning Division; in charge of Credit Guarantee Department; Director, BML General Laboratory June 2020 Representative Director; Vice President; General Manager, Management Division; in charge of Credit Guarantee Department; Director, BML General Laboratory; General Manager, Overseas Business Office June 2022 Representative Director; Vice President in charge of BML Clinical Testing Headquarters and in charge of Management Division; Director, BML General Laboratory; General Manager, Overseas Business Office To present </p> <p data-bbox="427 846 1283 1144"> (Reasons for nomination) Dr. Nobuki Arai has abundant experience and deep insight on overall medical industry from his experience as a doctor. Since assuming position as a Director in June 2009, he has served in inspection, sales, planning and quality divisions, and after assuming position as Representative Director in June 2017, he has involved in the Company's overall business including overseas and management divisions. By utilizing such achievements, expertise as well as insights on management, the Company has judged that he is personnel necessary to increase the future corporate value of the Group, and therefore nominates him again as a candidate for Director. </p>	70,137


No.	Name (Date of birth)	Past experience, positions and responsibilities in the Company	Number of shares of the Company held
3	 <p data-bbox="209 689 384 808">Norihisa Takebe (April 28, 1962) (Reappointment)</p>	<p data-bbox="432 271 1273 887"> April 2015 Joined the Company; General Manager, Sales Management Department; General Manager, Accounting Department April 2016 Operating Officer; General Manager, Corporate Planning Department; General Manager, Related Business Department; General Manager, Sales Management Department; General Manager, Accounting Department June 2016 Director; Operating Officer; Deputy General Manager, Planning Division; General Manager, Corporate Planning Department; General Manager, Related Business Department; General Manager, Sales Management Department; General Manager, Accounting Department June 2021 Director; Executive Officer; General Manager, Planning Division; General Manager, Corporate Planning Department; General Manager, Sales Management Department; General Manager, Accounting Department June 2022 Director; Senior Executive Officer; General Manager, Planning Division; General Manager, Corporate Planning Department; General Manager, Sales Management Department; General Manager, Accounting Department; General Manager, Related Business Department To present </p> <p data-bbox="421 920 1262 1158"> (Reasons for nomination) Mr. Norihisa Takebe has knowledge and experience of financial business. Since joining the Company, he has involved mainly in accounting, corporate planning and group company management divisions and has abundant experience and deep insight on the Company's overall business. By utilizing such achievements, expertise as well as insights on management, the Company has judged that he is personnel necessary to increase the future corporate value of the Group, and therefore nominates him again as a candidate for Director. </p>	4,461

No.	Name (Date of birth)	Past experience, positions and responsibilities in the Company	Number of shares of the Company held
4	 <p data-bbox="188 674 400 797">Hideaki Osawa (February 13, 1964) (Reappointment)</p>	<p data-bbox="421 271 1294 680"> September 1986 Joined the Company July 2008 General Manager, Kinki Sales Department June 2010 Representative Director, Japan Clinical Service, Inc. April 2016 Operating Officer; Deputy General Manager, Sales Management Division; General Manager, Tokyo Branch June 2019 Director; Operating Officer; Deputy General Manager, Sales Management Division; General Manager, Proposal Planning Department April 2021 Director; Operating Officer; General Manager, Sales Management Division; General Manager, Sales Promotion Headquarters; General Manager, Solution Proposal Department; General Manager, Medical Research Business Division To present </p> <p data-bbox="421 712 1294 952"> (Reasons for nomination) Since joining the Company, Mr. Hideaki Osawa has involved mainly in sales division and also served as Representative Director at a collection and delivery-related subsidiary, and he has abundant experience and deep insight on the Company's overall business. By utilizing such achievements, expertise as well as insights on management, the Company has judged that he is personnel necessary to increase the future corporate value of the Group, and therefore nominates him again as a candidate for Director. </p>	4,002

No.	Name (Date of birth)	Past experience, positions and responsibilities in the Company	Number of shares of the Company held
5	 <p data-bbox="188 703 400 824">Kenji Shibata (December 20, 1959) (Reappointment)</p>	<p data-bbox="432 271 1273 797"> April 1984 Joined the Company April 2014 General Manager, Inspection Department I June 2017 Director, Morioka Medical Laboratories, Inc. June 2018 Operating Officer; General Manager, Planning Division of the Company June 2022 Director; Operating Officer; General Manager, BML Clinical Testing Headquarters; General Manager, Inspection Planning Department, General Manager, General Laboratory First Clinical Testing Department; General Manager, General Laboratory Second Clinical Testing Department; General Manager, General Laboratory Fourth Clinical Testing Department April 2023 Director; Operating Officer; General Manager, BML Clinical Testing Headquarters; General Manager, Inspection Planning Department, General Manager, General Laboratory Second Clinical Testing Department; General Manager, General Laboratory Fourth Clinical Testing Department To present </p> <p data-bbox="432 831 1273 1068"> (Reasons for nomination) Since joining the Company, Mr. Kenji Shibata has been involved mainly in inspection division and has abundant experience and deep insight on the Company's overall business. By utilizing such achievements, expertise as well as insights on strategy planning, the Company has judged that he is personnel necessary to increase the future corporate value of the Group, and therefore nominates him again as a candidate for Director. </p>	4,901

No.	Name (Date of birth)	Past experience, positions and responsibilities in the Company	Number of shares of the Company held
6	 <p data-bbox="209 622 384 745">Yuji Yamashita (August 6, 1965) (Reappointment)</p>	<p data-bbox="432 271 1283 479">November 1988 Joined the Company April 2020 General Manager, Laboratory Information System Department July 2020 Operating Officer; Deputy General Manager, System Division; General Manager, Core System Department June 2022 Director; Operating Officer; General Manager, System Division To present</p> <p data-bbox="432 510 1283 745">(Reasons for nomination) Since joining the Company, Mr. Yuji Yamashita has been involved mainly in the systems division and has abundant experience and deep insight on the Company's overall business. By utilizing such achievements, expertise as well as insights on strategy planning, the Company has judged that he is personnel necessary to increase the future corporate value of the Group, and therefore nominates him again as a candidate for Director.</p>	1,987

No.	Name (Date of birth)	Past experience, positions and responsibilities in the Company	Number of shares of the Company held
7	 <p data-bbox="209 815 384 994">Yukiko Yoritaka (July 9, 1964) (Reappointment) (Outside) (Independent)</p>	<p data-bbox="432 271 1283 887"> April 1987 Joined The Sumitomo Bank, Limited (currently Sumitomo Mitsui Banking Corporation) April 2016 Executive Officer; General Manager, Learning and Development Institute, Human Resources Department, Sumitomo Mitsui Banking Corporation; Representative Director and President, SMBC LEARNING SUPPORT CO., LTD. April 2017 Executive Officer; General Manager, Learning and Development Institute, Human Resources Department, Sumitomo Mitsui Banking Corporation; Representative Director and President, SMBC LEARNING SUPPORT CO., LTD.; Executive Officer; General Manager, Learning and Development Institute, Human Resources Department, Sumitomo Mitsui Financial Group, Inc. April 2020 Executive Officer; Deputy in charge of Human Resources Department, Sumitomo Mitsui Banking Corporation; Executive Officer; Deputy in charge of Human Resources Department, Sumitomo Mitsui Financial Group, Inc. June 2020 Outside Director of the Company (incumbent) May 2021 Managing Director, The Japan Research Institute, Limited; Executive Officer, Sumitomo Mitsui Financial Group, Inc. To present </p> <p data-bbox="432 893 1043 987"> [Significant concurrent positions] • Managing Director, The Japan Research Institute, Limited • Executive Officer, Sumitomo Mitsui Financial Group, Inc. </p> <p data-bbox="432 1021 1257 1471"> (Reasons for nomination as a candidate for Outside Director and summary of expected roles) Ms. Yukiko Yoritaka has abundant experience and deep insights on finance and human resources fields. By utilizing such achievements, expertise as well as insights on management, the Company judged that she is personnel necessary to increase future corporate value of the Group through giving opinions and making judgements from an objective standpoint when making decisions for the management of the Company, and through playing a role of monitoring and supervising Directors' execution of duties, and therefore nominates her again as a candidate for Outside Director. The Company expects her to fulfill her role of supervising the management from a position independent from executive officers by utilizing her wealth of experience in finance and human resources fields. It has been three years since the appointment of Ms. Yukiko Yoritaka as Outside Director of the Company as of the conclusion of this Annual General Meeting of Shareholders. </p>	276

No.	Name (Date of birth)	Past experience, positions and responsibilities in the Company	Number of shares of the Company held
8	 <p data-bbox="193 712 395 779">Tatsuharu Arai (October 20, 1956)</p> <p data-bbox="193 808 395 898">(Reappointment) (Outside) (Independent)</p>	<p data-bbox="427 271 1287 786"> April 1982 Joined Showa Denko K.K. March 2004 General Manager, Production Technology Department, Kawasaki Plant March 2006 Head, Kawasaki Plant January 2008 General Manager, Electronic Chemicals Department, Chemicals Division, Head Office March 2010 General Manager, Production Technology Department, Head Office January 2012 Corporate Officer; Representative, Oita Complex, Oita Plant January 2014 Corporate Officer; General Manager, Petrochemicals Division, Head Office January 2017 Managing Corporate Officer; General Manager, Petrochemicals Division January 2018 President and Representative Director, UNION SHOWA K.K. January 2021 Corporate Advisor June 2021 Outside Director of the Company To present </p> <p data-bbox="427 824 1287 1270"> (Reasons for nomination as a candidate for Outside Director and summary of expected roles) Mr. Tatsuharu Arai has many years of abundant experience and deep insights on corporate management in the chemical industry. By utilizing such achievements, expertise as well as insights on management, the Company judged that he is personnel necessary to increase future corporate value of the Group through giving opinions and making judgements from an objective standpoint when making decisions for the management of the Company, and through playing a role of monitoring and supervising Directors' execution of duties, and therefore nominates him again as a candidate for Outside Director. The Company expects him to fulfill his role of supervising the management from a position independent from executive officers by utilizing his wealth of experience in the chemical field. It has been two years since the appointment of Mr. Tatsuharu Arai as Outside Director of the Company as of the conclusion of this Annual General Meeting of Shareholders. </p>	0

No.	Name (Date of birth)	Past experience, positions and responsibilities in the Company	Number of shares of the Company held
9	 <p>Shigeru Osawa (May 13, 1957)</p> <p>(Reappointment) (Outside) (Independent)</p>	<p>April 1980 Joined The Kyowa Bank, Ltd. (currently Resona Bank, Limited)</p> <p>April 2002 Tsubasa Systems Co., Ltd.</p> <p>June 2006 Managing Officer, Yahagi Construction Co., Ltd.</p> <p>June 2007 Director and Senior Managing Officer</p> <p>June 2010 Representative Director and Senior Managing Officer</p> <p>April 2012 Vice President and Representative Director</p> <p>June 2021 Advisor</p> <p>June 2022 Outside Director of the Company</p> <p>To present</p> <p>[Significant concurrent positions]</p> <p>• Advisor, Yahagi Construction Co., Ltd.</p> <p>(Reasons for nomination as a candidate for Outside Director and summary of expected roles)</p> <p>Mr. Shigeru Osawa has abundant experience and deep insights in the financial and construction fields. By utilizing such achievements, expertise as well as insights on management, the Company judged that he is personnel necessary to increase future corporate value of the Group through giving opinions and making judgements from an objective standpoint when making decisions for the management of the Company, and through playing a role of monitoring and supervising Directors' execution of duties, and therefore nominates him again as a candidate for Outside Director. The Company expects him to fulfill his role of supervising the management from a position independent from executive officers by utilizing his wealth of experience in the construction field.</p> <p>It has been one year since the appointment of Mr. Shigeru Osawa as Outside Director of the Company as of the conclusion of this Annual General Meeting of Shareholders.</p>	0

(Notes)

1. There are no special interests between the candidates for Directors and the Company.
2. Attendance at meetings of the Board of Directors by Mr. Kenji Shibata, Yuji Yamashita, and Mr. Shigeru Osawa aggregates the number of the meetings held after he assumed office as Director.
3. Ms. Yukiko Yoritaka, Mr. Tatsuharu Arai, and Mr. Shigeru Osawa are candidates for Outside Directors.
4. The Company has registered Ms. Yukiko Yoritaka, Mr. Tatsuharu Arai, and Mr. Shigeru Osawa as Independent Directors with the Tokyo Stock Exchange.
5. The Company has entered into an agreement with Ms. Yukiko Yoritaka, Mr. Tatsuharu Arai, and Mr. Shigeru Osawa in accordance with Article 427, Paragraph 1 of the Companies Act to limit their liability for damages under Article 423, Paragraph 1 of the same act. The maximum amount of liability for damages pursuant to the agreement is the minimum amount stipulated by laws and regulations. If they are reelected and assume office as Outside Directors of the Company, the agreement shall continue to be effective.
6. The Company has concluded with an insurance company a directors and officers liability insurance contract as stipulated in Article 430-3, Paragraph 1 of the Companies Act. This contract covers damages that may arise due to the insured being liable for performance of duties or receiving a claim related to the pursuit of such liability. However, the contract includes certain exclusions, such as no coverage for liability resulting from actions taken with the knowledge that they violate laws and regulations. The Company bears all of the insurance premium for the directors and officers liability insurance contract. Each candidate will be insured under the said insurance contract. The directors and officers liability insurance contracts shall be renewed on March 1, 2024, in the middle of each candidate's term of office.
7. The number of shares of the Company held by each candidate for Director refers to the actual number of shares held by each of them including the shares under the BML Group officers' shareholding association.

Proposal 4: Election of 1 Substitute Corporate Auditor

In order to prepare for cases where a vacancy results in a shortfall in the number of Corporate Auditors prescribed by laws and regulations, we propose the election of one Substitute Corporate Auditor.

The Board of Corporate Auditors has previously given its approval to this proposal.

The candidate for Substitute Corporate Auditor is as follows:

Name (Date of birth)	Past experience and significant concurrent positions	Number of shares of the Company held
Shunsuke Nohara (November 11, 1979) (Outside) (Independent)	October 2006 Registered as attorney at law (Dai-ichi Tokyo Bar Association) Joined KOHWA SOHGOH LAW OFFICES August 2015 Joined Kelvin Chia Partnership January 2016 Admitted as attorney at law in New York, USA October 2016 Partner, KOHWA SOHGOH LAW OFFICES (incumbent) To present (Reasons for nomination as a candidate for Substitute Outside Corporate Auditor) The Company proposes that Mr. Shunsuke Nohara be elected as Substitute Corporate Auditor since we judged that his expertise as an attorney at law and abundant experience as a corporate lawyer can be used for enhancing the audit structure of the Company, even though he has never been involved in corporate management.	0

(Notes)

1. Mr. Shunsuke Nohara is a candidate for Substitute Outside Corporate Auditor.
2. The Company has not entered into an advisory contract with the candidate.
3. The Company has entered into agreements with Outside Corporate Auditors in accordance with Article 427, Paragraph 1 of the Companies Act to limit their liability for damages pursuant to Article 423, Paragraph 1 of the same act. The maximum amount of liability for damages pursuant to the agreement is the minimum amount stipulated by laws and regulations. If the candidate is elected and assumes office as Outside Corporate Auditor, the Company intends to conclude the same agreement with him.
4. The Company has concluded with an insurance company a directors and officers liability insurance contract as stipulated in Article 430-3, Paragraph 1 of the Companies Act. This contract covers damages that may arise due to the insured being liable for performance of duties or receiving a claim related to the pursuit of such liability. However, the contract includes certain exclusions, such as no coverage for liability resulting from actions taken with the knowledge that they violate laws and regulations. The Company bears all of the insurance premium for the directors and officers liability insurance contract. If the candidate assumes office as Outside Corporate Auditor, he will be insured under the said insurance contract.
5. Mr. Shunsuke Nohara satisfies the requirement as Independent Corporate Auditor prescribed by the Tokyo Stock Exchange. If he assumes office as Outside Corporate Auditor, the Company will register him as an Independent Corporate Auditor with the Tokyo Stock Exchange.

(Reference) Composition of the Board (after this General Meeting of Shareholders)

Director

Name	Positions in the Company	Areas which the Company specifically expect candidates for Directors to cover							
		Management Experience	Medical Experience	Inspection/Engineering	Information Technology	Strategy Planning	Finance/Accounting	Personnel/Labor	Risk/Legal Affairs
Kensuke Kondo	President and Representative Director	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>			<input type="checkbox"/>
Nobuki Arai	Representative Director; Vice President	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>		<input type="checkbox"/>	
Norihisa Takebe	Representative Director and Senior Managing Officer	<input type="checkbox"/>				<input type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>
Hideaki Osawa	Director; Operating Officer					<input type="checkbox"/>			
Kenji Shibata	Director; Operating Officer			<input type="checkbox"/>		<input type="checkbox"/>			
Yuji Yamashita	Director; Operating Officer			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>			
Yukiko Yoritaka	Outside Director						<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Tatsuharu Arai	Outside Director	<input type="checkbox"/>		<input type="checkbox"/>					
Shigeru Osawa	Outside Director	<input type="checkbox"/>		<input type="checkbox"/>		<input type="checkbox"/>	<input type="checkbox"/>		

Corporate Auditors:

Name	Positions in the Company	Areas which the Company specifically expect candidates for Corporate Auditors to cover							
		Management Experience	Medical Experience	Inspection/Engineering	Information Technology	Strategy Planning	Finance/Accounting	Personnel/Labor	Risk/Legal Affairs
Kenichi Morishita	Corporate Auditor						<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Nobushige Tokuono	Outside Corporate Auditor						<input type="checkbox"/>	<input type="checkbox"/>	
Masato Denawa	Outside Corporate Auditor							<input type="checkbox"/>	<input type="checkbox"/>

The above list does not present all of the knowledge and experience possessed by the candidates.